Cargando…

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

BACKGROUND: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non‐HA population. As new therapies are introduced, a uniform approach to the assessment of mortality is required for comprehensive evaluation of risk–benefit pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pipe, Steven W., Kruse‐Jarres, Rebecca, Mahlangu, Johnny N., Pierce, Glenn F., Peyvandi, Flora, Kuebler, Peter, De Ford, Christian, Sanabria, Fabián, Ko, Richard H., Chang, Tiffany, Hay, Charles R. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756842/
https://www.ncbi.nlm.nih.gov/pubmed/33331042
http://dx.doi.org/10.1111/jth.15186
_version_ 1783626630352076800
author Pipe, Steven W.
Kruse‐Jarres, Rebecca
Mahlangu, Johnny N.
Pierce, Glenn F.
Peyvandi, Flora
Kuebler, Peter
De Ford, Christian
Sanabria, Fabián
Ko, Richard H.
Chang, Tiffany
Hay, Charles R. M.
author_facet Pipe, Steven W.
Kruse‐Jarres, Rebecca
Mahlangu, Johnny N.
Pierce, Glenn F.
Peyvandi, Flora
Kuebler, Peter
De Ford, Christian
Sanabria, Fabián
Ko, Richard H.
Chang, Tiffany
Hay, Charles R. M.
author_sort Pipe, Steven W.
collection PubMed
description BACKGROUND: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non‐HA population. As new therapies are introduced, a uniform approach to the assessment of mortality is required for comprehensive evaluation of risk–benefit profiles, timely identification of emerging safety signals, and comparisons between treatments. OBJECTIVES: Develop and test a framework for consistent reporting and analysis of mortality across past, current, and future therapies. PATIENTS/METHODS: We identified known causes of mortality in PwcHA through literature review, analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, and expert insights. Leading causes of death in general populations are those recognized by the Centers for Disease Control and Prevention and the World Health Organization. We developed an algorithm for assessing fatalities in PwcHA and used this to categorize FAERS data as a proof of concept. RESULTS: PwcHA share mortality causes with the non‐HA population including cardiovascular disease, malignancy, infections, pulmonary disease, dementias, and trauma/suicide. Causes associated with HA include hemorrhage, thrombosis, human immunodeficiency virus, hepatitis C virus, and liver dysfunction. We propose an algorithm employing these classes to categorize fatalities and use it to classify FAERS fatality data between 01/01/2000 and 03/31/2020; the most common causes were hemorrhage (22.2%) and thrombosis (10.4%). CONCLUSIONS: A conceptual framework for examining mortality in PwcHA receiving any hemophilia therapy is proposed to analyze and interpret fatalities, enabling consistent and objective assessment. Application of the framework using FAERS data suggests a generally consistent pattern of reported mortality across HA treatments, supporting the utility of this unified approach.
format Online
Article
Text
id pubmed-7756842
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77568422020-12-28 Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database Pipe, Steven W. Kruse‐Jarres, Rebecca Mahlangu, Johnny N. Pierce, Glenn F. Peyvandi, Flora Kuebler, Peter De Ford, Christian Sanabria, Fabián Ko, Richard H. Chang, Tiffany Hay, Charles R. M. J Thromb Haemost Original Articles BACKGROUND: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non‐HA population. As new therapies are introduced, a uniform approach to the assessment of mortality is required for comprehensive evaluation of risk–benefit profiles, timely identification of emerging safety signals, and comparisons between treatments. OBJECTIVES: Develop and test a framework for consistent reporting and analysis of mortality across past, current, and future therapies. PATIENTS/METHODS: We identified known causes of mortality in PwcHA through literature review, analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, and expert insights. Leading causes of death in general populations are those recognized by the Centers for Disease Control and Prevention and the World Health Organization. We developed an algorithm for assessing fatalities in PwcHA and used this to categorize FAERS data as a proof of concept. RESULTS: PwcHA share mortality causes with the non‐HA population including cardiovascular disease, malignancy, infections, pulmonary disease, dementias, and trauma/suicide. Causes associated with HA include hemorrhage, thrombosis, human immunodeficiency virus, hepatitis C virus, and liver dysfunction. We propose an algorithm employing these classes to categorize fatalities and use it to classify FAERS fatality data between 01/01/2000 and 03/31/2020; the most common causes were hemorrhage (22.2%) and thrombosis (10.4%). CONCLUSIONS: A conceptual framework for examining mortality in PwcHA receiving any hemophilia therapy is proposed to analyze and interpret fatalities, enabling consistent and objective assessment. Application of the framework using FAERS data suggests a generally consistent pattern of reported mortality across HA treatments, supporting the utility of this unified approach. John Wiley and Sons Inc. 2020-12-16 2021-01 /pmc/articles/PMC7756842/ /pubmed/33331042 http://dx.doi.org/10.1111/jth.15186 Text en © 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Pipe, Steven W.
Kruse‐Jarres, Rebecca
Mahlangu, Johnny N.
Pierce, Glenn F.
Peyvandi, Flora
Kuebler, Peter
De Ford, Christian
Sanabria, Fabián
Ko, Richard H.
Chang, Tiffany
Hay, Charles R. M.
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
title Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
title_full Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
title_fullStr Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
title_full_unstemmed Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
title_short Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
title_sort establishment of a framework for assessing mortality in persons with congenital hemophilia a and its application to an adverse event reporting database
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756842/
https://www.ncbi.nlm.nih.gov/pubmed/33331042
http://dx.doi.org/10.1111/jth.15186
work_keys_str_mv AT pipestevenw establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT krusejarresrebecca establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT mahlangujohnnyn establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT pierceglennf establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT peyvandiflora establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT kueblerpeter establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT defordchristian establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT sanabriafabian establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT korichardh establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT changtiffany establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase
AT haycharlesrm establishmentofaframeworkforassessingmortalityinpersonswithcongenitalhemophiliaaanditsapplicationtoanadverseeventreportingdatabase